Nasdaq FDA - Search News

Atara extends losses after FDA clinical hold

Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo. Read more here.

Business Insider · 1d

Atara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL Issues

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence:

Reuters on MSN · 2d

US FDA puts clinical hold on Atara's trials for cancer cell therapies

Atara Biotherapeutics said on Tuesday the U.S. health regulator had placed a clinical hold on its trials for cancer cell therapies, sending the drug developer's shares down more than 4% in premarket trading.

Hosted on MSN · 2d

Sanofi says FDA lifted clinical hold on trial for Cialis OTC switch

Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a trial designed to test an over-the-counter version of its erectile dysfunction (ED) drug,

Business Insider · 2d

Atara Biotherapeutics Faces Uncertainty Amid FDA Clinical Hold and Financing Needs, Resulting in Hold Rating

Atara Biotherapeutics (ATRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin

11hon MSN

Ionis stock rises on FDA, EMA nod for SMA drug dose increase

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the ...

Hosted on MSN8h

Beta Bionics joins IPO uptick, aims to raise $114.4m in Nasdaq listing

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now set its financial goalposts, aiming to raise $114.4m from the initial public ...

Nasdaq13d

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

The FDA filing is supported by data from the phase ... We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that ...

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...

2don MSN

Replimune stock soars on FDA priority review for melanoma treatment

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug ...

Nasdaq13d

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

The FDA has now notified the company that its sNDA ... We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that ...

Investor's Business Daily on MSN6d

Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of ...

Hosted on MSN2d

Surging stocks and FDA approval propel Koh Young’s U.S. market ambitions

Koh Young Technology, a South Korean mid-sized company specializing in 3D inspection equipment, has seen its stock price ...

Nasdaq7d

ImmunityBio Provides Update On FDA Submissions For 2025

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results